Ipsen S.A.
IPN.PA - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$12.65B
Close$
$198.67
29.9% upside
Current Fair Value
29.9% upsideUndervalued by 29.9% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $12.65 Billion |
|---|---|
| Enterprise Value | $11.64 Billion |
| Annual dividend | $1.60 |
| Dividend yield | 1.06% |
| Earnings per Share | $5.37 |
| Beta | 0.32 |
| Outstanding Shares | 82,709,453 |
Return
| Return on Equity | 20.38% |
|---|---|
| Return on Assets | 12.87% |
| Return on Invested Capital | 31.12% |
Valuation & Multiples
| P/E Ratio | 24.39 |
|---|---|
| PEG | 117.88 |
| Price to Sales | 1.61 |
| Price to Book Ratio | 2.73 |
| Enterprise Value to Revenue | 1.47 |
| Enterprise Value to EBIT | 6.53 |
| Enterprise Value to Net Income | 12 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.2 |
Revenue Sources
No data
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$6.49
Consensus analyst estimateRevenue Estimate
$2.12 B
Consensus analyst estimateNext Earnings Call
Expected Date
February 11, 2027
EPS Estimate
$7.88
Consensus analyst estimateRevenue Estimate
$2.36 B
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Ipsen S.A.
5,535 employees
CEO: David G. Loew
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and ac...